This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
B cell lymphoma	F-box protein 11 (FBXO11); B cell CLL lymphoma 6 (BCL6)	<i>In vitro</i> and mouse studies suggest increasing FBXO11 levels could help treat BCL6-overexpressing diffuse large B cell lymphoma (DLBCL). FBXO11 is a component of the ubiquitin complex that degrades the pro-oncogenic BCL6. The <i>FBXO11</i> gene was deleted or mutated in 14.8% and 14.3% of human DLBCL cell lines, respectively. In <i>FBXO11</i> -deleted DLBCL cell lines, vector-mediated reconstitution of FBXO11 led to BCL6 degradation and cell death. In mice bearing <i>FBXO11</i> -deleted DLBCL cells, vector-mediated reconstitution of <i>FBXO11</i> suppressed tumor growth compared with that seen using empty vector control. Next steps could include identifying a strategy to upregulate FBXO11.	Patent and licensing status unavailable	Duan, S. <i>et al. Nature</i> ; published online Nov. 23, 2011; doi:10.1038/nature10688 Contact: Michele Pagano, New York University School of Medicine, New York, N.Y. e-mail: michele.pagano@nyumc.org Contact: Roberto Chiarle, University of Turin, Turin, Italy e-mail: roberto.chiarle@unito.it
SciBX 4(48); doi:10.1038/scibx.2011.1346 Published online Dec. 15, 2011				